During the past decade, Center for Biomedical Research conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 8 clinical trials were completed, i.e. on average, 114.3% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Center for Biomedical Research" #1 sponsor was "ACADIA Pharmaceuticals Inc." with 2 trials, followed by "Celldex Therapeutics" with 2 trials sponsored, "Genentech, Inc." with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored and "United Therapeutics" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Center for Biomedical Research" #1 collaborator was "National Cancer Institute (NCI)" with 3 trials as a collaborator, "Alzheimer's Association" with 1 trials as a collaborator, "Alzheimer's Drug Discovery Foundation" with 1 trials as a collaborator, "Cancer and Leukemia Group B" with 1 trials as a collaborator and "Children's Oncology Group" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Center for Biomedical Research" are "Non-Small Cell Lung Cancer" (4 trials), "Breast Cancer" (3 trials), "Neuropsychiatric Symptoms Related to Neurodegenerative Disease" (2 trials), "Advanced Breast Cancer" (1 trials) and "Alzheimer Disease" (1 trials). Many other conditions were trialed in "Center for Biomedical Research" in a lesser frequency.

Most popular intervention types in "Center for Biomedical Research" are "Drug" (17 trials), "Biological" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Docetaxel" (3 trials), "Placebo" (3 trials), "CDX-011" (2 trials), "Capecitabine" (2 trials) and "Pimavanserin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Center for Biomedical Research" are 19 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Center for Biomedical Research". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Center for Biomedical Research, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Center for Biomedical Research, 1 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".